Financial Data and Key Metrics Changes - In Q4 2025, the company achieved revenue of $1.405 billion, representing a 7% increase year-over-year, and full-year revenue of $5.101 billion, up 5% [13][22] - Adjusted EBITDA for Q4 was $330 million, a 27% increase year-over-year, with an adjusted EBITDA margin of 23.5%, the highest since the company's IPO [12][20] - The full-year adjusted EBITDA was $891 million, reflecting a strong operating leverage and financial discipline [20][23] Business Line Data and Key Metrics Changes - Vision Care segment revenue for Q4 was $778 million, up 5%, with full-year revenue of $2.923 billion, up 6% [15] - Surgical segment revenue in Q4 was $249 million, a 3% increase, with full-year revenue of $894 million, up 4% [17] - Pharma segment revenue for Q4 was $378 million, a 14% increase, with full-year revenue of $1.284 billion, up 6% [18] Market Data and Key Metrics Changes - The U.S. branded RX business in the pharma segment grew by 21% in Q4 and 13% for the full year, driven by strong performance from MIEBO [18] - Contact lens revenue grew by 8% in Q4 and 7% for the full year, with daily SiHy lenses showing significant growth [16] - The international market for contact lenses grew by 6% in Q4, with China seeing a 7% increase [16] Company Strategy and Development Direction - The company is focused on executing its three-year plan, emphasizing operational excellence and financial discipline to drive sustained growth [5][6] - There is a strong commitment to expanding the dry eye portfolio, with MIEBO expected to exceed peak sales of $600 million due to its successful market penetration [26][27] - The company aims to leverage its diversified product offerings to maintain a competitive advantage in the eye health market [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow faster than the market in 2026, with expectations for revenue growth across all segments [22][23] - The company highlighted the importance of execution and operational improvements as key drivers of future success [36][38] - Management acknowledged the competitive landscape but remains optimistic about the company's positioning and product quality [53][56] Other Important Information - The company expects adjusted EBITDA growth of approximately 15% year-over-year for 2026, with a focus on margin expansion [23][24] - The adjusted tax rate for the full year 2025 was 10%, lower than previous guidance, primarily due to one-time adjustments [21] Q&A Session Summary Question: What are the key areas to execute for growth in 2026? - Management emphasized the importance of execution and structural improvements in the P&L, highlighting the successful implementation of Vision 2027 [36][38] Question: What lessons can be learned from MIEBO's success? - Management noted that strong execution and a positive benefit-risk profile contributed to MIEBO's success, which will inform future pipeline strategies [40][41] Question: How will MIEBO's growth trajectory be impacted by steady investments? - Management expects continued strong growth for MIEBO, with a focus on targeted investments as the product transitions from launch to growth phase [48][51] Question: What are the competitive dynamics in the market? - Management acknowledged competition but expressed confidence in their strong market position, particularly in the pharma segment with leading products [53][56]

Group 1 - The core viewpoint of the articles highlights EssilorLuxottica's commitment to innovation and consumer empowerment in vision health, showcased during the China International Import Expo (CIIE) [1][2] - EssilorLuxottica is celebrating its 30th anniversary in China and has introduced several new products focused on myopia management for children and adolescents, adult vision health, and wearable devices [1] - The company emphasizes collaboration with ecosystem partners to enhance consumer insights, industry standards, and public education on vision health [1] Group 2 - The launch of the new Essilor® Star Control® 2.0 lenses, which feature advanced H.A.L.T.MAX technology, aims to significantly improve the effectiveness of myopia prevention compared to previous versions [2] - A digital version of the educational resource "Our Eyes" has been developed to meet the needs of the digital age, incorporating the latest knowledge from the "Myopia Prevention White Paper (2025)" [2] - The new report, "National Vision Health Report (2026 Edition)," will focus on myopia prevention and expand to cover "lifecycle eye health," leveraging successful experiences in the field [1]

Core Insights - The eighth China International Import Expo (CIIE) is being held from November 5 to 10, marking the 30th anniversary of China's opening up, with EssilorLuxottica participating as a consistent exhibitor for eight years [1] - EssilorLuxottica is showcasing new products in areas such as myopia management for children and adolescents, adult vision health, and wearable devices, while also collaborating with ecosystem partners on consumer insights, industry standards, and public education [1] - The company aims to leverage innovation to reshape consumer experiences in vision care, focusing on classic brands, medical technology, and wearable devices [1] Company Initiatives - EssilorLuxottica is launching the Star Control 2.0 lenses, which feature enhanced optical technology to significantly improve the effectiveness of myopia prevention compared to previous versions [2] - The company is also releasing a digital version of "Our Eyes," a 3D book that has been well-received since its 2020 launch, aimed at educating children and adolescents about eye health through engaging multimedia content [2] - The new "National Vision Health Report (2026 Edition)" is being developed to address myopia prevention and expand to a "lifecycle eye health" approach, utilizing successful experiences from the myopia prevention field [1][2]